This series of discoveries strongly suggests that SELL, CD79B, and RAMP2 have the potential to emerge as novel and highly promising prognostic indicators and therapeutic targets in the field of GC, opening up new perspectives and possibilities for precision medicine in this disease. The gene discussed is CD79B; the disease is gastric cancer.